Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy-Reference-Cited by-同舟云学术

Factors Affecting the Comprehension of Outpatients Receiving Cancer Chemotherapy

Published:2023-03-01 Issue:3 Volume:46 Page:505-510
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Nishibe-Toyosato Seira¹,Ando Yosuke¹,Nakasuji Nayu²,Hayashi Takahiro¹,Ito Kaori³,Matsuda Hidezo²,Tsujii Naho²,Tsuge Masahiro¹,Imaizumi Kazuyoshi⁴,Kawada Kenji⁵,Yamada Shigeki²

Affiliation:

1. Department of Clinical Pharmacy, Fujita Health University School of Medicine

2. Department of Pharmacy, Fujita Health University Hospital

3. Department of Hematology, Fujita Health University School of Medicine

4. Department of Respiratory Medicine, Fujita Health University School of Medicine

5. Department of Medical Oncology, Fujita Health University School of Medicine

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/46/3/46_b22-00374/_pdf

Reference25 articles.

1. 1) Cancer Information Services, National Cancer Center, Japan: ‹https://ganjoho.jp/reg_stat/statistics/stat/annual.html›, accessed 19 May, 2022.

2. 2) Boucher J, Lucca J, Hooper C, Pedulla L, Berry DL. A structured nursing intervention to address oral chemotherapy adherence in patients with non-small cell lung cancer. Oncol. Nurs. Forum, 42, 383–389 (2015).

3. 3) Tokdemir G, Kav S. The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. Asia Pac. J. Oncol. Nurs., 4, 290–298 (2017).

4. 4) Sommers RM, Miller K, Berry DL. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol. Nurs. Forum, 39, E373–E379 (2012).

5. 5) Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 31, 3327–3334 (2013).